A new peer-reviewed study published in PLOS One has provided evidence that pentosan polysulfate sodium delivers sustained clinical, functional, and structural benefits in osteoarthritis, reinforcing its potential as a disease-modifying therapy.

Chimeric Therapeutics (ASX:CHM) has announced that its CHM CDH17 CAR-T program has advanced to Dose Level 3. This is the highest dose tier in the Phase 1 portion of its ongoing trial.

Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.

Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.

Algorae Pharmaceuticals (ASX:1AI) has taken another step in building a diversified commercial medicines platform, finalising a new licensing and supply agreement that broadens its reach beyond oncology into cardiovascular and metabolic disease markets.

Arovella Therapeutics (ASX:ALA) is entering a period of board renewal as the biotechnology company advances toward a critical clinical inflection point.

Immutep (ASX:IMM) has passed a key clinical milestone, achieving 50 per cent patient enrolment in its pivotal global Phase 3 trial evaluating a novel immunotherapy combination for first-line non-small cell lung cancer.

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies.

Neuren Pharmaceuticals said FDA feedback has clarified the regulatory path for NNZ-2591 in HIE and Pitt Hopkins syndrome, supporting continued US development while European uncertainty persists following a negative EMA trend vote on its licensed Rett syndrome therapy, trofinetide.

Trajan Group (ASX:TRJ) has reaffirmed its full-year financial year 2026 guidance after a subdued start to the year gave way to a stronger second quarter, positioning the global analytical science and device group for improved performance in the second half.

Arovella Therapeutics (ASX:ALA) has entered a pivotal new phase of development after securing US Food and Drug Administration acceptance of its Investigational New Drug application for ALA-101.

Ovarian cancer remains notoriously difficult to diagnose at an early stage, with symptoms that are often vague, non-specific and easily mistaken for less serious conditions.